TRCT
FDMT icon

Tower Research Capital (TRC)’s 4D Molecular Therapeutics FDMT Stock Holding History

Tower Research Capital (TRC)’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$56K Buy
6,018
+3,799
+171% +$33.1K ﹤0.01% 2644
2025
Q4 		$16.6K Buy
2,219
+71
+3% +$720 ﹤0.01% 3240
2025
Q3 		$18.7K Sell
2,148
-5,506
-72% -$32.9K ﹤0.01% 3373
2025
Q2 		$28.4K Buy
7,654
+2,876
+60% +$10.1K ﹤0.01% 3454
2025
Q1 		$15.4K Sell
4,778
-45,475
-90% -$214K ﹤0.01% 3221
2024
Q4 		$280K Buy
50,253
+37,102
+282% +$291K 0.01% 1466
2024
Q3 		$142K Buy
13,151
+3,583
+37% +$59.5K ﹤0.01% 1945
2024
Q2 		$201K Buy
9,568
+8,586
+874% +$215K ﹤0.01% 2074
2024
Q1 		$31.3K Sell
982
-8,643
-90% -$221K ﹤0.01% 2615
2023
Q4 		$195K Buy
9,625
+8,506
+760% +$112K ﹤0.01% 2115
2023
Q3 		$14.2K Sell
1,119
-1,913
-63% -$32K ﹤0.01% 3701
2023
Q2 		$54.8K Sell
3,032
-5,334
-64% -$98.2K ﹤0.01% 2513
2023
Q1 		$144K Buy
8,366
+4,638
+124% +$90.2K ﹤0.01% 1559
2022
Q4 		$83K Sell
3,728
-673
-15% -$10.4K ﹤0.01% 1980
2022
Q3 		$35K Sell
4,401
-2,502
-36% -$22.7K ﹤0.01% 3468
2022
Q2 		$48K Buy
6,903
+5,121
+287% +$49.8K ﹤0.01% 2922
2022
Q1 		$27K Sell
1,782
-1,927
-52% -$30.3K ﹤0.01% 3248
2021
Q4 		$81K Buy
3,709
+610
+20% +$15K ﹤0.01% 2372
2021
Q3 		$84K Buy
3,099
+2,129
+219% +$60.7K ﹤0.01% 2534
2021
Q2 		$23K Buy
970
+366
+61% +$11.2K ﹤0.01% 3753
2021
Q1 		$26K Buy
+604
New +$26.8K ﹤0.01% 3677

Other funds holding FDMT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Tower Research Capital (TRC)'s FDMT Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its 4D Molecular Therapeutics (FDMT) stake by 171% in Q1 2026, buying an estimated $33.1K and bringing the position to 6,018 shares worth $56K. The position accounts for ﹤0.01% of the portfolio, ranked #2644.

Tower Research Capital (TRC) first reported a position in FDMT in Q1 2021 and has held it in 21 quarters since. The position peaked at $280K in Q4 2024. 152 funds tracked by Wall St. Rank hold FDMT as of Q1 2026.

  • Tower Research Capital (TRC) held 6,018 shares of 4D Molecular Therapeutics worth $56K as of Q1 2026.
  • Tower Research Capital (TRC) bought 3,799 4D Molecular Therapeutics shares in Q1 2026, an estimated $33.1K.
  • 4D Molecular Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #2644 holding.
  • Tower Research Capital (TRC) first reported a position in 4D Molecular Therapeutics in Q1 2021 and has held it in 21 quarters since.
  • Tower Research Capital (TRC)'s 4D Molecular Therapeutics position peaked at $280K in Q4 2024.
  • 152 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.